Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
192.3 EUR | -1.33% | -1.31% | -10.18% |
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- The firm trades with high earnings multiples: 25.99 times its 2024 earnings per share.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-10.18% | 10.63B | - | ||
+23.13% | 52.73B | B- | ||
+37.49% | 39B | A | ||
-8.73% | 38.52B | B | ||
+28.09% | 30.38B | B | ||
-12.26% | 26.39B | C | ||
+10.57% | 26.08B | B- | ||
+45.05% | 14.15B | B+ | ||
+32.23% | 12.6B | C+ | ||
-6.56% | 11.51B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- CRL Stock
- RV6 Stock
- Ratings Charles River Laboratories International, Inc.